AbbVie Inc. buy melinda
Summary
This prediction ended on 30.08.17 with a price of €66.78. With a performance of 2.81%, the BUY prediction by melinda for AbbVie Inc. closed with a slight gain. melinda has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
AbbVie Inc. | -1.532% | -1.532% | 27.430% | 84.717% |
iShares Core DAX® | -1.414% | 7.218% | 17.151% | 15.732% |
iShares Nasdaq 100 | -2.316% | 4.450% | 18.360% | 30.945% |
iShares Nikkei 225® | -2.756% | 10.071% | 10.704% | 2.733% |
iShares S&P 500 | -1.849% | 4.760% | 19.639% | 34.852% |
According to melinda what are the pros and cons of AbbVie Inc. for the foreseeable future?
Pros
Cons
Comments by melinda for this prediction
In the thread AbbVie Inc. diskutieren
Die FDA erteilt Zulassung Mavyret Abbvie Inc.
$
Stopped prediction by melinda for AbbVie Inc.
AbbVie Inc.
17.06.23
17.06.24
18.06.24
AbbVie Inc.
05.06.22
05.06.23
06.06.23
AbbVie Inc.
01.11.19
04.11.21
05.11.21
AbbVie Inc.
15.06.18
17.12.18
17.12.18
AbbVie Inc.
28.03.18
23.05.18
23.05.18
AbbVie Inc.
12.03.18
28.03.18
28.03.18
AbbVie Inc.
10.09.17
28.09.17
28.09.17
AbbVie Inc.
10.09.17
28.09.17
28.09.17
AbbVie Inc.
10.08.17
30.08.17
30.08.17
AbbVie Inc.
07.05.16
12.05.16
12.05.16